Glyconics is a company at the forefront of diagnostic innovation, using infrared spectroscopy to analyse samples for markers of disease across a wide range of conditions.
|Address:||St John’s Innovation Centre, Cowley Road, Cambridge|
|Membership type:||Professional Individual and Corporate < 5 (£50+VAT pa)|
4 million people globally will end up in hospital at a cost of £14bn. Using Infrared spectroscopy, our hand-held device can diagnose and predict days before when such acute attack will happen so saving time, money and lives. Our platform can be used for a wide range of acute and chronic conditions.
Glyconics are in the Business Weekly Top 50 Cambridge companies to watch and won EU awards and UK grants.
A hand-held device that would give early warning of ‘acute events’- and so avoid the hospitalisation of thousands of patients with chronic obstructive pulmonary disease (COPD) - is to go into production ahead of clinical trials. This follows an agreement between medical diagnostics company Glyconics and Spectrolytic, a leading developer of infrared (IR) spectrometers.
3 August 2018Read in full